HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.